Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.46 |
| ▸ | RORC | P51449 | 4/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481232 | 1.00 | USP30 (0.46) | USP30RORCGPR119JAK2JAK1 | |
| SCHEMBL21773364 | 1.00 | USP30 (0.46) | USP30RORCGPR119JAK2JAK1 | |
| SCHEMBL1617581 | 0.84 | RORC (0.48) | USP30RORCGPR119JAK2JAK1 | |
| SCHEMBL21748783 | 0.82 | ALDH1A1 (0.39) | KDM4E | |
| SCHEMBL29960225 | 0.79 | RORC (0.47) | USP30RORCGPR119JAK2JAK1 | |
| SCHEMBL21748845 | 0.79 | POLB (0.43) | USP30GPR119MAPK1 | |
| SCHEMBL21748843 | 0.79 | POLB (0.43) | USP30GPR119MAPK1 | |
| SCHEMBL30783231 | 0.79 | POLB (0.43) | USP30GPR119MAPK1 | |
| SCHEMBL31649176 | 0.76 | USP30 (0.43) | USP30RORCGPR119JAK2JAK1 | |
| SCHEMBL18759246 | 0.74 | GPR119 (0.55) | USP30RORCGPR119JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1553084-A1 | PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | OPRL1, OXTR, OPRM1 | USP30 2468/4885RORC 2424/4885GPR119 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.